Levetiracetam prescribing across the NHS.
Levetiracetam is modern epilepsy's default: 3.4m items a year, still growing, no enzyme interactions and no monitoring burden. Its rise is the quiet reason older agents decline; new epilepsy rarely starts anywhere else now.
The NHS in England dispensed 3,377,086 prescription items of Levetiracetam in the 12 months to July 2026, across primary care and hospitals.
Spending on Levetiracetam over those 12 months was £29.1m at net ingredient cost, the list price of what was dispensed before any discounts.
Items were up 4.0% on the previous 12 months.
63% of Levetiracetam volume moved through primary care and 37% through hospital pharmacies.
Levetiracetam ranks #4 of 30 chemical substances in Control of epilepsy (BNF 4.8.1), by items dispensed.
Among Integrated Care Boards, NHS North East and North Cumbria ICB dispensed the highest volume of Levetiracetam.
Source: NHS Business Services Authority open data (English Prescribing Data and SCMD), OGL v3.0. Items count prescriptions dispensed, not patients treated.
Diamond markers show events around this period: NICE decisions, safety alerts, supply notices, Drug Tariff moves and price concessions, new suppliers in dm+d and framework awards. Hover a marker for the date and type. The evidence behind each one, with the source quote and link, sits behind Apply.
| Month | Items | Spend (NIC) |
|---|---|---|
| July 2026 | 301,648 | £2.6m |
| June 2026 | 288,939 | £2.4m |
| May 2026 | 274,976 | £2.3m |
| April 2026 | 282,192 | £2.3m |
| March 2026 | 286,085 | £2.4m |
| February 2026 | 261,532 | £2.1m |
| January 2026 | 283,356 | £2.3m |
| December 2025 | 296,472 | £2.6m |
| November 2025 | 268,238 | £2.4m |
| October 2025 | 287,547 | £2.5m |
| September 2025 | 280,384 | £2.6m |
| August 2025 | 265,717 | £2.5m |
The same series as the chart, most recent month first. The full monthly history, as CSV, sits behind Apply.
10.0% of its class.
Levetiracetam ranks #4 of 30 chemical substances in Control of epilepsy (BNF 4.8.1), by items dispensed in July 2026. The full class league, who's gaining, and the month-by-month share movement sit behind Apply.
Average items by calendar month across the full history, indexed to the annual mean.
39 suppliers hold a live levetiracetam listing, across 150 packs.
A A H Pharmaceuticals Ltd, Abacus Medicine Ltd, Accord-UK Ltd, Alliance Healthcare (Distribution) Ltd, Amarox Ltd, Bowmed Ibisqus Ltd, Brillpharma Ltd, Bristol Laboratories Ltd, Brown & Burk UK Ltd, Crescent Pharma Ltd, CST Pharma Ltd, Desitin Pharma Ltd, Esteve Pharmaceuticals Ltd, Hikma Pharmaceuticals International Ltd, Kent Pharma (UK) Ltd, Lexon (UK) Ltd, Medihealth (Northern) Ltd, Medley Pharma Ltd, Milpharm Ltd, Necessity Supplies Ltd, Neuraxpharm UK Ltd, Novumgen Ltd, Pfizer Ltd, Pharmaram Ltd, Pilsco Ltd, Relonchem Ltd, Rivopharm (UK) Ltd, Sandoz Ltd, Seacross Pharmaceuticals Ltd, Sigma Pharmaceuticals Plc, Special Order, Strides Pharma UK Ltd, Sun Pharma UK Ltd, SyriMed, Tillomed Laboratories Ltd, Torrent Pharma (UK) Ltd, UCB Pharma Ltd, Wockhardt UK Ltd, Zentiva Pharma UK Ltd. In the last twelve months 0 packs were listed and 4 discontinued. Every pack, its GTIN and published list price, and each week's changes are in the full report.
A listing in the NHS Dictionary of Medicines and Devices means a product may be supplied. It says nothing about sales or market share, and the list price is the reimbursement price, not what any buyer pays. Contains information from dm+d 10.1.0, published by the NHS Business Services Authority under the Open Government Licence v3.0.
Levetiracetam across all 36 ICBs.
Every Integrated Care Board in England, shaded by how much levetiracetam its GPs dispense per head of population. Hover an ICB to name it. The ranked figures for all 36 ICBs, and the drill-down to practice level, are in the full report.
Darker shading marks where Levetiracetam is dispensed most per head of population. Exact figures for every ICB, and the drill-down to practice level, are in the full report.
Zoomed out to the 7 NHS regions.
The same 12 months rolled up to NHS England's seven regions, ranked by intensity.
The teaser view.
Three rows each. The full 36-ICB view, every prescribing organisation, every strength and the hospital picture sit below the fold, behind Apply.
- 1 NHS North East and North Cumbria ICB 238k
- 2 NHS West and North London ICB 233k
- 3 NHS Greater Manchester ICB 188k
- – + 33 more. See the full 36-ICB table. See all →
- 1 NHS North East London ICB +8.3%
- 2 NHS Lincolnshire ICB +6.9%
- 3 NHS Black Country ICB +6.8%
- – + 33 more. See every ICB, ranked. See all →
- 1 Levetiracetam 500mg tablets 37%
- 2 Levetiracetam 250mg tablets 24%
- 3 Levetiracetam 1g tablets 17%
- – + 3 more. See every strength and pack. See all →
Split of items across NHSBSA primary care and SCMD hospital dispensing.
Prescribing by deprivation.
Items per 1,000 registered patients by deprivation decile (1 = most deprived), practice deprivation weighted by where each practice's patients live. Read the shape rather than the absolute level: the most and least deprived deciles cover far fewer practices, and age structure drives much of the gradient.
The devolved nations.
| Nation | Items · 12 months | Data to |
|---|---|---|
| England | 3.4m | July 2026 |
| Scotland | 225k | June 2026 |
| Northern Ireland | 90k | May 2026 |
| Wales | 189k | April 2026 |
Each nation publishes its own community prescribing data, with different coding and list rules, so read these per-nation rather than as an exact UK total. Sources: NHSBSA (England), Public Health Scotland, NHS Wales Shared Services Partnership, OpenDataNI. Used under the Open Government Licence v3.0.
What open data won't tell you about levetiracetam.
Prescribing volume tracks prevalence and habit together; the data cannot show which starts are new epilepsy and which are switches from older drugs.
Asked and answered.
Is levetiracetam prescribing rising or falling in the NHS?
Rising. England dispensed 3,377,086 items of Levetiracetam in the 12 months to July 2026, up 4.0% on the previous 12 months. Items count prescriptions dispensed, not patients treated, so the change can reflect dose and duration shifts as well as patient numbers.
How much does the NHS spend on levetiracetam?
£29.1m at net ingredient cost in the 12 months to July 2026. Net ingredient cost is the list price of the medicine before discounts and rebates; the NHS's final bill, especially for hospital medicines, is usually lower.
Where in England is levetiracetam prescribed most?
By raw volume, NHS North East and North Cumbria ICB dispensed the most levetiracetam in the last 12 months. Raw volume favours the biggest populations; the map on this page shades every ICB by items per head to correct for that.
How up to date is this data?
This page runs to July 2026, the most recent NHSBSA release. Prescribing data publishes roughly six to eight weeks in arrears, and DoseTrend refreshes within 48 hours of each monthly release.
The full breakdown.
Every ICB, every prescribing organisation, every strength, the hospital view with what trusts paid and who holds each framework line, Signals with their sources, and the monthly briefing PDF. The rows below are placeholders; the real tables sit behind the application.
Related pages.
See the full molecule directory, or read about the data and pricing.
Track levetiracetam like this, every month.
£1,500 a month per molecule. Apply and we'll pre-fill Levetiracetam for you.